Literature DB >> 11029398

Selective downregulation of VEGF-A(165), VEGF-R(1), and decreased capillary density in patients with dilative but not ischemic cardiomyopathy.

D Abraham1, R Hofbauer, R Schäfer, R Blumer, P Paulus, A Miksovsky, H Traxler, A Kocher, S Aharinejad.   

Abstract

Cardiomyopathy (CM) comprises a heterogeneous group of diseases, including ischemic (ICM) and dilative (DCM) forms. The pathogenesis of primary DCM is not clearly understood. Recent studies in mice show that vascular endothelial growth factor (VEGF) is involved in ICM. Whether VEGF plays a role in human CM is unknown. We examined the mRNA and protein expression of VEGF and its receptors in hearts of patients with end-stage DCM and ICM and in healthy individuals using real-time polymerase chain reaction and Western blotting. Number of capillaries, area of myocytes, and collagen were calculated in cardiac biopsies using transmission electron microscopy. In DCM, except for VEGF-C, mRNA transcript levels of VEGF-A(165), VEGF-A(189), and VEGF-B and the protein level of VEGF-A and VEGF-R(1) were downregulated compared with controls (P:<0.05). However, in ICM, mRNA transcript levels of VEGF isoforms and protein levels of VEGF-C were upregulated. The vascular density was decreased in DCM but increased in ICM compared with controls (P:<0. 05). Muscular hypertrophy was not different for ICM and DCM, although DCM had more collagen (P:<0.05). Blunted VEGF-A and VEGF-R(1) protein expression and downregulated mRNA of the predominant isoform of VEGF-A, VEGF-A(165), to our knowledge shown here for the first time, provide evidence that the VEGF-A defect in DCM is located upstream. Whether downregulation of certain VEGF isoforms in DCM is a cause or consequence of this disorder remains unclear, although upregulated VEGF levels in ICM are most likely the result of ischemia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11029398     DOI: 10.1161/01.res.87.8.644

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  40 in total

1.  Decreased serum vascular endothelial growth factor concentrations in patients with congestive heart failure.

Authors:  H Arakawa; U Ikeda; Y Hojo; S Ueno; M Nonaka-Sarukawa; K Yamamoto; K Shimada
Journal:  Heart       Date:  2003-02       Impact factor: 5.994

2.  Identification of a specific pattern of downregulation in expression of isoforms of vascular endothelial growth factor in dilated cardiomyopathy.

Authors:  R A De Boer; R H Henning; R A Tio; Y M Pinto; R M H J Brouwer; R J Ploeg; M Böhm; W H Van Gilst; D J Van Veldhuisen
Journal:  Heart       Date:  2002-10       Impact factor: 5.994

3.  Activation of host tissue trophic factors through JAK-STAT3 signaling: a mechanism of mesenchymal stem cell-mediated cardiac repair.

Authors:  Arsalan Shabbir; David Zisa; Huey Lin; Michalis Mastri; Gregory Roloff; Gen Suzuki; Techung Lee
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-09-17       Impact factor: 4.733

4.  The vascular marker soluble fms-like tyrosine kinase 1 is associated with disease severity and adverse outcomes in chronic heart failure.

Authors:  Bonnie Ky; Benjamin French; Kosha Ruparel; Nancy K Sweitzer; James C Fang; Wayne C Levy; Douglas B Sawyer; Thomas P Cappola
Journal:  J Am Coll Cardiol       Date:  2011-07-19       Impact factor: 24.094

5.  Intramyocardial VEGF-B167 gene delivery delays the progression towards congestive failure in dogs with pacing-induced dilated cardiomyopathy.

Authors:  Martino Pepe; Mohammed Mamdani; Lorena Zentilin; Anna Csiszar; Khaled Qanud; Serena Zacchigna; Zoltan Ungvari; Uday Puligadda; Silvia Moimas; Xiaobin Xu; John G Edwards; Thomas H Hintze; Mauro Giacca; Fabio A Recchia
Journal:  Circ Res       Date:  2010-04-29       Impact factor: 17.367

6.  Defining the molecular signatures of human right heart failure.

Authors:  Jordan L Williams; Omer Cavus; Emefah C Loccoh; Sara Adelman; John C Daugherty; Sakima A Smith; Benjamin Canan; Paul M L Janssen; Sara Koenig; Crystal F Kline; Peter J Mohler; Elisa A Bradley
Journal:  Life Sci       Date:  2018-01-31       Impact factor: 5.037

7.  Pediatric and adult dilated cardiomyopathy represent distinct pathological entities.

Authors:  Meghna D Patel; Jayaram Mohan; Caralin Schneider; Geetika Bajpai; Enkhsaikhan Purevjav; Charles E Canter; Jeffrey Towbin; Andrea Bredemeyer; Kory J Lavine
Journal:  JCI Insight       Date:  2017-07-20

8.  Stromal cell-derived CSF-1 blockade prolongs xenograft survival of CSF-1-negative neuroblastoma.

Authors:  Dietmar Abraham; Karin Zins; Mouldy Sioud; Trevor Lucas; Romana Schäfer; E Richard Stanley; Seyedhossein Aharinejad
Journal:  Int J Cancer       Date:  2010-03-15       Impact factor: 7.396

Review 9.  Vascular dysfunction in idiopathic dilated cardiomyopathy.

Authors:  Santiago Roura; Antoni Bayes-Genis
Journal:  Nat Rev Cardiol       Date:  2009-07-28       Impact factor: 32.419

10.  Ischemic patterns assessed by positron emission tomography predict adverse outcome in patients with idiopathic dilated cardiomyopathy.

Authors:  Richard M de Jong; Rene A Tio; Pim van der Harst; Adriaan A Voors; Paul M Koning; Clark J A M Zeebregts; Dirk J van Veldhuisen; Rudi A J O Dierckx; Riemer H J A Slart
Journal:  J Nucl Cardiol       Date:  2009-08-01       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.